Jump to main content.


Aldicarb Quickview (CASRN 116-06-3)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Aldicarb

File First On-Line: 01/31/1987; Last Significant Revision: 11/01/1993

Category (section)
Status
Last Revised
Oral RfD Assessment On-line 11/01/1993
Inhalation RfC Assessment No data
Carcinogenicity Assessment On-line 03/01/1991
Synonyms
  • 116-06-3
  • Aldecarb
  • Aldicarb
  • Ambush
  • Carbamyl
  • Carbanolate
  • ENT 27,093
  • 2-Methyl-2-(methylthio)propanal, o-((methylamino)carbonyl) oxime
  • 2-Methyl-2-(methylthio)propionaldehyde o-(methylcarbamoyl)oxime
  • NCI-c08640
  • OMS 771
  • more...
Aldicarb Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or befroe April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
UF RfD
Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects. Nausea, diarrhea, and other signs and symptoms. ) NOAEL : 1 x10-2 mg/kg-day 10 1 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • D (Not classifiable as to human carcinogenicity)
  • Weight-of-Evidence Narrative:
    • Aldicarb was not found to induce statistically significant increases in tumor incidence in mice or rats in feeding studies or mice in a skin painting study. In the feeding studies there were, however, significant trends in pituitary tumors in female rats and fibrosarcomas in the male mouse. This evidence, together with the fact that less than maximum tolerated doses were used, indicates that the available assays are inadequate to assess the carcinogenic potential of aldicarb.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.